CTXR Citius Pharmaceuticals Inc.

2.02
-0.06  -3%
Previous Close 2.08
Open 2.06
52 Week Low 0.415
52 Week High 2.9
Market Cap $254,085,884
Shares 125,785,091
Float 113,452,151
Enterprise Value $252,361,822
Volume 13,035,027
Av. Daily Volume 13,288,372
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
Mino-Lok
Catheter related blood stream infection
Phase 3
Phase 3
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Drug Pipeline

Drug Stage Notes
CITI-002
Hemorrhoids
Phase 2a
Phase 2a
Phase 2b trial to be initiated by end of 2021.

Latest News

  1. CRANFORD, N.J., Feb. 19, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) ("Citius" or the "Company"), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced that it has closed its previously announced sale of an aggregate of 50,830,566 shares of its common stock and accompanying warrants to purchase up to an aggregate of 25,415,283 shares of its common stock, at a purchase price of $1.505 per share and accompanying warrant in a registered direct offering priced at-the-market under Nasdaq rules.

    H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

    The warrants have an exercise price of $1.70 per share, are immediately exercisable, and…

    CRANFORD, N.J., Feb. 19, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) ("Citius" or the "Company"), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced that it has closed its previously announced sale of an aggregate of 50,830,566 shares of its common stock and accompanying warrants to purchase up to an aggregate of 25,415,283 shares of its common stock, at a purchase price of $1.505 per share and accompanying warrant in a registered direct offering priced at-the-market under Nasdaq rules.

    H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

    The warrants have an exercise price of $1.70 per share, are immediately exercisable, and will expire five years from the issue date.

    The aggregate gross proceeds to the Company from the offering are approximately $76.5 million, before deducting the placement agent fees and other offering expenses payable by the Company. Citius currently intends to use the net proceeds from the offering for general corporate purposes, including pre-clinical and clinical development of our product candidates and working capital and capital expenditures.

    The securities described above were offered pursuant to a "shelf" registration statement (File No. 333-248748) filed with the Securities and Exchange Commission (SEC) and declared effective on September 25, 2020, and an additional registration statement on Form S-3 (File No. 333-253179) filed on February 16, 2021 pursuant to Rule 462(b), which became effective automatically upon filing. The offering was made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and the accompanying prospectus relating to the securities that were offered has been filed with the SEC and is available at the SEC's website at www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus relating to the securities in the offering may also be obtained by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by calling (646) 975-6996 or emailing .

    This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

    About Citius Pharmaceuticals, Inc.

    Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. For more information, please visit www.citiuspharma.com.

    Forward Looking Statements

    This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price, and includes all statements related to the intended use of net proceeds from the registered direct offering.  Factors that could cause actual results to differ materially from those currently anticipated are: market and other conditions; our ability to successfully undertake and complete clinical trials and the results from those trials for our product candidates; our need for substantial additional funds; risks relating to the results of research and development activities; uncertainties relating to preclinical and clinical testing; the early stage of products under development; the estimated markets for our product candidates and the acceptance thereof by any market; risks related to our growth strategy; patent and intellectual property matters, our ability to attract, integrate, and retain key personnel; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; our dependence on third-party suppliers; government regulation; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

    Contact:

    Andrew Scott

    Vice President, Corporate Development

    (O) 908-967-6677 x105

     

     

    Cision View original content:http://www.prnewswire.com/news-releases/citius-pharmaceuticals-announces-closing-of-76-5-million-registered-direct-offering-priced-at-the-market-under-nasdaq-rules-301231912.html

    SOURCE Citius Pharmaceuticals, Inc.

    View Full Article Hide Full Article
  2. CRANFORD, N.J., Feb. 17, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) ("Citius" or the "Company"), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced that it has entered into definitive agreements with certain healthcare-focused and institutional investors for the purchase of an aggregate of 50,830,566 shares of its common stock and accompanying warrants to purchase up to an aggregate of 25,415,283 shares of its common stock, at a purchase price of $1.505 per share and accompanying warrant in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to take place on or about February 19, 2021, subject…

    CRANFORD, N.J., Feb. 17, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) ("Citius" or the "Company"), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced that it has entered into definitive agreements with certain healthcare-focused and institutional investors for the purchase of an aggregate of 50,830,566 shares of its common stock and accompanying warrants to purchase up to an aggregate of 25,415,283 shares of its common stock, at a purchase price of $1.505 per share and accompanying warrant in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to take place on or about February 19, 2021, subject to the satisfaction of customary closing conditions.

    H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

    The warrants have an exercise price of $1.70 per share, will be immediately exercisable, and will expire five years from the issue date.

    The aggregate gross proceeds to the Company from the offering are expected to be approximately $76.5 million, before deducting the placement agent fees and other offering expenses payable by the Company. Citius currently intends to use the net proceeds from the offering for general corporate purposes, including pre-clinical and clinical development of our product candidates and working capital and capital expenditures.

    The securities described above are being offered pursuant to a "shelf" registration statement (File No. 333-248748) filed with the Securities and Exchange Commission (SEC) and declared effective on September 25, 2020, and an additional registration statement on Form S-3 (File No. 333-253179) filed on February 16, 2021 pursuant to Rule 462(b), which became effective automatically upon filing. The offering is being made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and the accompanying prospectus relating to the securities being offered will be filed with the SEC and be available at the SEC's website at www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus relating to the securities being offered may also be obtained, when available, by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by calling (646) 975-6996 or emailing .   

    This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

    About Citius Pharmaceuticals, Inc.

    Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. For more information, please visit www.citiuspharma.com.

    Forward Looking Statements

    This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price, and includes all statements related to the completion of the registered direct offering, the satisfaction of customary closing conditions related to the registered direct offering and the intended use of net proceeds from the registered direct offering.  Factors that could cause actual results to differ materially from those currently anticipated are: market and other conditions; our ability to successfully undertake and complete clinical trials and the results from those trials for our product candidates; our need for substantial additional funds; risks relating to the results of research and development activities; uncertainties relating to preclinical and clinical testing; the early stage of products under development; the estimated markets for our product candidates and the acceptance thereof by any market; risks related to our growth strategy; patent and intellectual property matters, our ability to attract, integrate, and retain key personnel; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; our dependence on third-party suppliers; government regulation; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

    Contact:

    Andrew Scott

    Vice President, Corporate Development

    (O) 908-967-6677 x105

     

    Cision View original content:http://www.prnewswire.com/news-releases/citius-pharmaceuticals-announces-76-5-million-registered-direct-offering-priced-at-the-market-under-nasdaq-rules-301229588.html

    SOURCE Citius Pharmaceuticals, Inc.

    View Full Article Hide Full Article
  3. CRANFORD, N.J., Feb. 16, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ:CTXR), a specialty pharmaceutical company developing and commercializing critical care drug products, today issued a shareholder letter providing a corporate update on the Company's recent achievements and anticipated milestones for 2021.

    Highlights from the letter include:

    • Mino-Lok® pivotal trial interim analysis and review by the Data Monitoring Committee (DMC) expected in the second quarter
    • Halo-Lido IND (second quarter) and Phase 2b protocol to be filed afterwards
    • Mino-Wrap™ in pre-clinical development with plans to submit IND to the FDA by the end of the year
    • NoveCite i-MSCs development is progressing with: ongoing data generation…

    CRANFORD, N.J., Feb. 16, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ:CTXR), a specialty pharmaceutical company developing and commercializing critical care drug products, today issued a shareholder letter providing a corporate update on the Company's recent achievements and anticipated milestones for 2021.

    Highlights from the letter include:

    • Mino-Lok® pivotal trial interim analysis and review by the Data Monitoring Committee (DMC) expected in the second quarter
    • Halo-Lido IND (second quarter) and Phase 2b protocol to be filed afterwards
    • Mino-Wrap™ in pre-clinical development with plans to submit IND to the FDA by the end of the year
    • NoveCite i-MSCs development is progressing with: ongoing data generation from our proof-of-concept sheep acute respiratory distress syndrome (ARDS) model demonstrating impressive interim results (studies to be completed in second quarter); FDA-required GLP animal toxicology studies have been implemented; and development of an i-MSC master cell bank (MCB) followed by cGMP manufacturing is underway
    • Private placement for gross proceeds of $20.0 million and investors' exercise of warrants generating $4.5 million in gross proceeds completed in January 2021 and February 2021, respectively

    "Our important achievements against the COVID headwinds last year give us great confidence that 2021 will be a banner year for advancing our three product platforms in the clinic, and our corporate decision to commence the development of NoveCite next-generation cellular therapies further expands our goal as a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for significant unmet medical needs" said Myron Holubiak, President and CEO of Citius Pharmaceuticals. "Our advanced clinical program for Mino-Lok is moving forward with expected full enrollment for the Phase 3 pivotal trial this year. For Halo-Lido, we expect to file an Investigational New Drug Application (IND) for the combination by the second quarter  and initiate our Phase 2b trial by year-end. We also plan to start pre-clinical pharmacology and toxicology studies for Mino-Wrap within the next few months along with chemistry, manufacturing and controls (CMC) development, and we target filing an IND by the end of 2021. In addition to the plans described above for our NoveCite i-MSCs Program, we plan to submit an IND to the FDA and initiate our Phase 1 first-in-human clinical trial in COVID-19 ARDS by the end of the second quarter of 2022. Our recent $20 million private round of financing and investors' exercise of warrants for net proceeds of approximately $4.5 million provides significant financial runway to move forward with our three programs in the clinic, as well as manufacturing development for our unique induced-mesenchymal stem cell therapy for ARDS associated with COVID-19. We are excited about the road ahead and thankful as always for the ongoing support of our shareholders."

    To read the Shareholder Letter in its entirety, please visit the Company's Investor Info website at ir.citiuspharma.com.

    About Citius Pharmaceuticals, Inc.

    Citius is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. For more information, please visit www.citiuspharma.com.

    Safe Harbor

    This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "plan," "expect," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks associated with conducting clinical trials and drug development, including anticipated development timelines and study results; risks relating to the results of research and development activities; uncertainties relating to preclinical and clinical testing; the early stage of products under development; our dependence on third-party suppliers; our need for substantial additional funds; patent and intellectual property matters; market and other conditions; our ability to attract, integrate, and retain key personnel; the estimated markets for our product candidates and the acceptance thereof by any market; risks related to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

    Contact:

    Andrew Scott

    Vice President, Corporate Development

    (O) 908-967-6677 x105

    (M) 646-522-8410

    Cision View original content:http://www.prnewswire.com/news-releases/citius-pharmaceuticals-issues-shareholder-letter-with-corporate-update-on-recent-achievements-and-anticipated-milestones-for-2021-301228425.html

    SOURCE Citius Pharmaceuticals, Inc.

    View Full Article Hide Full Article
  4. NEW YORK, Feb. 8, 2021 /PRNewswire/ -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the February 4th Small and Microcap Showcase are now available for on-demand viewing.

    REGISTER OR LOGIN NOW TO VIEW THE PRESENTATIONS: https://bit.ly/3pPZeWX

    The company presentations will be available 24/7 for 90 days. Investors, advisors and analysts may download shareholder materials from the "virtual trade booth" for the next three weeks.

    Participating Companies:

    Full Company

    Legal Name - Presentation Name

    Ticker

    Keynote Presentation: Investing 101: Evaluating a Public Company's Corporate Communications Efforts

    Skyline Corporate Communications Group, LLC



    Lleidanetworks Serveis Telematics S. A.

    (OTCQX:LLEIF, BME: LLN, EPA: ALLLN)))

    Mirriad Advertising plc

    (OTCQB:MMDDF, LON: MIRI)))

    Alvopetro Energy Ltd.

    (OTCQX:ALVOF, TSXV:ALV)

    Genprex, Inc.

    (NASDAQ:GNPX)

    BioSig Technologies, Inc.

    (NASDAQ:BSGM)

    VolitionRx Limited

    (NYSE:VNRX)

    Earthasia International Holdings Ltd.

    (OTCQX:ETIHY, HKEx: 6128)))

    Citius Pharmaceuticals, Inc.

    (NASDAQ:CTXR)

    VERB Technology Company, Inc.

    (NASDAQ:VERB)

    Logiq, Inc.

    (OTCQX:LGIQ)

    Clean Energy Technologies, Inc.

    (OTCQB:CETY)

    Slinger Bag Inc.

    (OTCQB:SLBG)

    Skye Bioscience, Inc.

    (OTCQB:SKYE)

    Experion Holdings Ltd.

    (OTCQB:EXPFF, TSXV:EXP)

    BIGG Digital Assets Inc.

    (OTCQB:BBKCF, CSE:BIGG)

    NexTech AR Solutions

    (OTCQB:NEXCF, NEO: NTAR.NE, CSE:NTAR)

    To facilitate investor relations scheduling, for more information about the program and to view a complete calendar of Virtual Investor Conferences, please visit www.virtualinvestorconferences.com.

    About Virtual Investor Conferences®

    Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly-traded companies to meet and present directly with investors.

    A real-time solution for investor engagement, Virtual Investor Conferences is part of OTC Market Group's suite of investor relations services specifically designed for more efficient Investor Access.  Replicating the look and feel of on-site investor conferences, Virtual Investor Conferences combine leading-edge conferencing and investor communications capabilities with a comprehensive global investor audience network.

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/small-and-microcap-company-investor-presentations-now-available-for-on-demand-viewing-301223706.html

    SOURCE VirtualInvestorConferences.com

    View Full Article Hide Full Article
  5. Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations

    NEW YORK, Feb. 8, 2021 /CNW/ - Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the February 4th Small and Microcap Showcase are now available for on-demand viewing.

    REGISTER OR LOGIN NOW TO VIEW THE PRESENTATIONS: https://bit.ly/3pPZeWX

    The company presentations will be available 24/7 for 90 days. Investors, advisors and analysts may download shareholder materials from the "virtual trade booth" for the next three weeks.

    Participating Companies:

    Full Company
    Legal Name - Presentation Name

    Ticker

    Keynote Presentation: Investing 101:

    Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations

    NEW YORK, Feb. 8, 2021 /CNW/ - Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the February 4th Small and Microcap Showcase are now available for on-demand viewing.

    REGISTER OR LOGIN NOW TO VIEW THE PRESENTATIONS: https://bit.ly/3pPZeWX

    The company presentations will be available 24/7 for 90 days. Investors, advisors and analysts may download shareholder materials from the "virtual trade booth" for the next three weeks.

    Participating Companies:

    Full Company

    Legal Name - Presentation Name

    Ticker

    Keynote Presentation: Investing 101: Evaluating a Public

    Company's Corporate Communications Efforts

    Skyline Corporate Communications Group, LLC



    Lleidanetworks Serveis Telematics S. A.

    ((LLEIF, BME: LLN, EPA: ALLLN))

    Mirriad Advertising plc

    ((MMDDF, LON: MIRI))

    Alvopetro Energy Ltd.

    ((ALVOF, TSXV:ALV)

    Genprex, Inc.

    ((GNPX)

    BioSig Technologies, Inc.

    ((BSGM)

    VolitionRx Limited

    ((VNRX)

    Earthasia International Holdings Ltd.

    ((ETIHY, HKEx: 6128))

    Citius Pharmaceuticals, Inc.

    ((CTXR)

    VERB Technology Company, Inc.

    ((VERB)

    Logiq, Inc.

    (OTCQX: LGIQ)

    Clean Energy Technologies, Inc.

    ((CETY)

    Slinger Bag Inc.

    ((SLBG)

    Skye Bioscience, Inc.

    ((SKYE)

    Experion Holdings Ltd.

    ((EXPFF, TSXV:EXP)

    BIGG Digital Assets Inc.

    ((BBKCF, CSE:BIGG)

    NexTech AR Solutions

    ((NEXCF, NEO: NTAR.NE, CSE:NTAR)

    To facilitate investor relations scheduling, for more information about the program and to view a complete calendar of Virtual Investor Conferences, please visit www.virtualinvestorconferences.com.

    About Virtual Investor Conferences®

    Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly-traded companies to meet and present directly with investors.

    A real-time solution for investor engagement, Virtual Investor Conferences is part of OTC Market Group's suite of investor relations services specifically designed for more efficient Investor Access.  Replicating the look and feel of on-site investor conferences, Virtual Investor Conferences combine leading-edge conferencing and investor communications capabilities with a comprehensive global investor audience network.

    SOURCE VirtualInvestorConferences.com

    Cision View original content: http://www.newswire.ca/en/releases/archive/February2021/08/c5124.html

    View Full Article Hide Full Article
View All Citius Pharmaceuticals Inc. News